Form 8-K Rapport Therapeutics, For: Sep 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Rapport Therapeutics terminates stock sales agreement prospectus
September 8, 2025 4:04 PM EDTRapport Therapeutics (NASDAQ: RAPP) terminated its at-the-market sales agreement prospectus effective September 8, 2025, according to a company statement.
The company ended the ATM prospectus filed with its Form S-3 registration statement related to common stock sales under a July 1, 2025 sales agreement with Leerink... More
